

In the claims:

Please cancel claims 56-59, 61-74, and 76-86 without prejudice and amend claims 1, 55, 60, and 75 as follows:

D1 15/17
1. (Amended) A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vitro*, thereby downregulating HIV-1 fusion cofactor expression in the T cell.

D2 15/17
55. (Amended) A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vitro*, thereby downregulating CCR5 expression in the T cell.

D3 15/17
60. (Amended) A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vivo*, thereby downregulating CCR5 expression in the T cell.

D4 15/17
75. (Amended) A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a solid phase surface comprising an anti-CD28 antibody and an anti-CD3 antibody *in vivo*, thereby downregulating HIV-1 fusion cofactor expression in the T cell.

Please add new claims 87-94 as follows:

D5 15/17
87. The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

88. The method of any one of claims 1, 55, 60, or 75, wherein the anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

89. The method of any one of claims 1, 55, 60, or 75, wherein said solid phase surface is a bead.

90. The method of claim 89, wherein the bead is a magnetic immunobead.